Trevi Therapeutics, Inc. (TRVI)
NASDAQ: TRVI · Real-Time Price · USD
12.93
+0.01 (0.08%)
Mar 5, 2026, 1:57 PM EST - Market open
Trevi Therapeutics Stock Forecast
Stock Price Forecast
The 12 analysts with 12-month price forecasts for Trevi Therapeutics stock have an average target of 20.38, with a low estimate of 12.5 and a high estimate of 27. The average target predicts an increase of 57.62% from the current stock price of 12.93.
Analyst Consensus: Strong Buy
* Price targets were last updated on Jan 9, 2026.
Analyst Ratings
The average analyst rating for Trevi Therapeutics stock from 12 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 7 | 8 | 8 | 8 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 11 | 12 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $21 | Strong Buy | Reiterates | $21 | +62.41% | Jan 9, 2026 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $19 | Strong Buy | Maintains | $19 | +46.95% | Jan 8, 2026 |
| Stifel | Stifel | Strong Buy Maintains $15 → $18 | Strong Buy | Maintains | $15 → $18 | +39.21% | Dec 19, 2025 |
| Leerink Partners | Leerink Partners | Buy Maintains $13 → $16 | Buy | Maintains | $13 → $16 | +23.74% | Nov 20, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $19 | Strong Buy | Maintains | $19 | +46.95% | Nov 14, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.38
from -0.47
EPS Next Year
-0.48
from -0.38
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||
| Avg | n/a | n/a | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -0.37 | -0.23 | ||||
| Avg | -0.38 | -0.48 | ||||
| Low | -0.40 | -0.65 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.